Evaluation of Extended Infusion Set Wear Using Medtronic Extended Wear Sof-set Infusion Set
Evaluation of Extended Infusion Set Wear Using the Medtronic Extended Wear Sof-set Infusion Set
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Palo Alto, California, United States, 94304
- Stanford University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Clinical diagnosis of type 1 diabetes for at least one year and using an insulin pump for at least 12 months
- The diagnosis of type 1 diabetes is based on the investigator's judgment; C-peptide level and antibody determinations are not needed.
- Age 18 to 55 years
- Hemoglobin A1c level less than or equal to 8.5%
- Willing to use Novolog insulin while they are participating in the study
- Total daily insulin dose is at least 0.3 units/kg/day
- For females, not currently known to be pregnant
- An understanding of and willingness to follow the protocol and sign the informed consent
- Willingness to wear the experimental insulin infusion sets throughout the study
- Must be able to understand spoken and written English
Exclusion Criteria:
- Diabetic ketoacidosis in the past 3 months
- blood urea nitrogen (BUN), Creatinine, or liver function test (ALT or AST) more than three times the upper limit of normal, or thrombocytopenia
- Severe hypoglycemia resulting in seizure or loss of consciousness in the 3 months prior to enrollment
- Pregnant or lactating females
- Known tape allergies
- Current treatment for a seizure disorder
- Cystic fibrosis
- Active infection
- A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol such as the following examples:
- Inpatient psychiatric treatment in the past 6 months for either the subject or the subject's primary care giver (i.e., parent or guardian)
- Presence of a known adrenal disorder
- If on antihypertensive, thyroid, anti-depressant or lipid lowering medication, lack of stability on the medication for the past 2 months prior to enrollment in the study
- Abuse of alcohol
- Dialysis for renal failure
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Protocol 1: Standard then Extended Set
Participants will wear the control (standard) infusion set for 1 week, then switch to the experimental Extended Wear infusion set in combination with Heparin 400 IU for 1 week, then will repeat the cycle for a total of 4 weeks.
|
For two of the 4 weeks the Extended Wear insulin infusion set will be used.
For two of the 4 weeks the Standard infusion set will be used
Other Names:
|
|
Experimental: Protocol 1: Extended then Standard Set
Participants will wear the experimental Extended Wear infusion set in combination with Heparin 400 IU for 1 week, then switch to the control (standard) infusion set for 1 week, then will repeat the cycle for a total of 4 weeks.
|
For two of the 4 weeks the Extended Wear insulin infusion set will be used.
For two of the 4 weeks the Standard infusion set will be used
Other Names:
|
|
Experimental: Protocol 2 (Part 1): Sequence 1
Participants will wear the control (standard) infusion set for 1 week, then the Extended Wear infusion set with heparin at 40 IU (week 1), 80 IU (week 2), 120 IU (week 3), and 200 IU (week 4).
|
For two of the 4 weeks the Extended Wear insulin infusion set will be used.
For two of the 4 weeks the Standard infusion set will be used
Other Names:
|
|
Experimental: Protocol 2 (Part 1): Sequence 2
Participants will wear the Extended Wear infusion set with heparin at 40 IU (week 1), 80 IU (week 2), 120 IU (week 3), and 200 IU (week 4), then the control (standard) infusion set (week 5).
|
For two of the 4 weeks the Extended Wear insulin infusion set will be used.
For two of the 4 weeks the Standard infusion set will be used
Other Names:
|
|
Experimental: Protocol 2 (Part 1): Sequence 3
Participants will wear the Extended Wear infusion set with heparin at 80 IU (week 1), 120 IU (week 2), and 200 IU (week 3), then the control (standard) infusion set (week 4), then the Extended Wear infusion set with heparin at 40 IU (week 5).
|
For two of the 4 weeks the Extended Wear insulin infusion set will be used.
For two of the 4 weeks the Standard infusion set will be used
Other Names:
|
|
Experimental: Protocol 2 (Part 1): Sequence 4
Participants will wear the Extended Wear infusion set with heparin at 120 IU (week 1), and 200 IU (week 2), then the control (standard) infusion set (week 3), then the Extended Wear infusion set with heparin at 40 IU (week 4), and 80 IU (week 5).
|
For two of the 4 weeks the Extended Wear insulin infusion set will be used.
For two of the 4 weeks the Standard infusion set will be used
Other Names:
|
|
Experimental: Protocol 2 (Part 1): Sequence 5
Participants will wear the Extended Wear infusion set with heparin at 200 IU (week 1), then the control (standard) infusion set (week 2), then the Extended Wear infusion set with heparin at 40 IU (week 3), 80 IU (week 4), and 80 IU (week 5).
|
For two of the 4 weeks the Extended Wear insulin infusion set will be used.
For two of the 4 weeks the Standard infusion set will be used
Other Names:
|
|
Experimental: Protocol 2 (Part 2): Standard then Extended Set
Participants will wear the control (standard) infusion set for 1 week, then switch to the experimental Extended Wear infusion set in combination with Heparin 80 IU for 1 week, then will repeat the cycle for a total of 4 weeks.
|
For two of the 4 weeks the Extended Wear insulin infusion set will be used.
For two of the 4 weeks the Standard infusion set will be used
Other Names:
|
|
Experimental: Protocol 2 (Part 1): Extended then Standard Set
Participants will wear the experimental Extended Wear infusion set in combination with Heparin 80 IU for 1 week, then switch to the control (standard) infusion set for 1 week, then will repeat the cycle for a total of 4 weeks.
|
For two of the 4 weeks the Extended Wear insulin infusion set will be used.
For two of the 4 weeks the Standard infusion set will be used
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to an infusion set failure due to an occlusion
Time Frame: within 1 week
|
Glucose >250 mg/dL with failure of a correction dose to lower the glucose by 50 mg/dL, or ketones > or = 0.6 mg/dL with a glucose reading of >250 mg/dL (in the absence of illness), or a pump occlusion alarm
|
within 1 week
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
signs of infection at insulin infusion site
Time Frame: 1 week
|
erythema or induration of > 1cm in diameter at injection site
|
1 week
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IRB 36142
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.